Forest hits setback on new COPD drug, one of its key hopes for sales growth

Forest Laboratories ($FRX) will have to wait for that hoped-for revenue from its new combo LAMA/LABA chronic obstructive pulmonary disease (COPD) therapy--and it may have a tougher time building sales when the time comes. Forest and partner Almirall say they've decided to put off their application for FDA approval for a combination of aclidinium bromide, a long-acting muscarinic antagonist, and formoterol fumarate, a long-acting beta agonist. The delay could interfere with their plans to compete against rival drugs that could get to market first. Report

Suggested Articles

The future may be uncertain for AZ’s Imfinzi in first-line lung cancer, but its targeted med Tagrisso now boasts a green light in that setting.

Ultragenyx is back with another FDA nod, this time for Crysvita to treat X-linked hypophosphatemia in patients one year and older.

Roche got a two pieces of good Hemlibra news early this week—and what's good for Hemlibra must be good for Roche.